Kairos Pharma to Present at the LD Micro Main Event XVII
Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company, has announced its participation in the LD Micro Main Event XVII. The event is scheduled for October 28-30, 2024 at the Luxe Sunset Boulevard Hotel in Los Angeles.
Dr. John S. Yu, Chief Executive Officer of Kairos Pharma, will deliver a corporate overview during the conference. His presentation is set for Wednesday, October 30, 2024, at 12:00 PM PT.
Interested parties can register to watch the presentation online through the provided link: https://me24.sequireevents.com/
Kairos Pharma (NYSE American: KAPA), un'azienda biofarmaceutica in fase clinica, ha annunciato la sua partecipazione al LD Micro Main Event XVII. L'evento è in programma dal 28 al 30 ottobre 2024 presso il Luxe Sunset Boulevard Hotel di Los Angeles.
Il Dr. John S. Yu, Amministratore Delegato di Kairos Pharma, presenterà una durante la conferenza. La sua presentazione è prevista per mercoledì 30 ottobre 2024, alle 12:00 PM PT.
Le parti interessate possono registrarsi per seguire la presentazione online tramite il link fornito: https://me24.sequireevents.com/
Kairos Pharma (NYSE American: KAPA), una empresa biofarmacéutica en etapa clínica, ha anunciado su participación en el LD Micro Main Event XVII. El evento está programado para del 28 al 30 de octubre de 2024 en el Luxe Sunset Boulevard Hotel en Los Ángeles.
El Dr. John S. Yu, Director Ejecutivo de Kairos Pharma, ofrecerá una visión general corporativa durante la conferencia. Su presentación está programada para el miércoles 30 de octubre de 2024, a las 12:00 PM PT.
Las partes interesadas pueden registrarse para ver la presentación en línea a través del enlace proporcionado: https://me24.sequireevents.com/
카이로스 제약 (NYSE American: KAPA), 임상 단계의 생물의약품 회사,가 LD 마이크로 메인 이벤트 XVII에 참가한다고 발표했습니다. 이 이벤트는 2024년 10월 28일부터 30일까지 로스앤젤레스의 Luxe Sunset Boulevard Hotel에서 열릴 예정입니다.
카이로스 제약의 최고 경영자인 존 S. 유 박사가 컨퍼런스에서 기업 개요를 발표할 것입니다. 그의 발표는 2024년 10월 30일 수요일, 오후 12시 PT로 예정되어 있습니다.
관심 있는 분들은 제공된 링크를 통해 온라인으로 발표를 시청하기 위해 등록할 수 있습니다: https://me24.sequireevents.com/
Kairos Pharma (NYSE American: KAPA), une entreprise bio-pharmaceutique en phase clinique, a annoncé sa participation à l'LD Micro Main Event XVII. L'événement est prévu du 28 au 30 octobre 2024 au Luxe Sunset Boulevard Hotel à Los Angeles.
Le Dr John S. Yu, Président-directeur général de Kairos Pharma, présentera un aperçu de l'entreprise pendant la conférence. Sa présentation est programmée pour le mercredi 30 octobre 2024, à 12h00 PT.
Les parties intéressées peuvent s'inscrire pour regarder la présentation en ligne via le lien fourni : https://me24.sequireevents.com/
Kairos Pharma (NYSE American: KAPA), ein biopharmazeutisches Unternehmen in klinischen Phasen, hat seine Teilnahme an der LD Micro Main Event XVII bekannt gegeben. Die Veranstaltung ist für 28. bis 30. Oktober 2024 im Luxe Sunset Boulevard Hotel in Los Angeles angesetzt.
Dr. John S. Yu, Chief Executive Officer von Kairos Pharma, wird während der Konferenz einen Unternehmensüberblick geben. Seine Präsentation ist für Mittwoch, den 30. Oktober 2024, um 12:00 Uhr PT geplant.
Interessierte Parteien können sich über den bereitgestellten Link zur Online-Übertragung der Präsentation registrieren: https://me24.sequireevents.com/
- None.
- None.
LOS ANGELES, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced today that John S. Yu, M.D., Chief Executive Officer, will present a corporate overview at the LD Micro Main Event XVII. The conference is being held on October 28 – 30, 2024 at the Luxe Sunset Boulevard Hotel in Los Angeles.
| Event: | LD Micro Main Event XVII |
| Presentation Date: | Wednesday, October 30, 2024 |
| Time: | 12:00 PM PT |
| Register to watch presentation: | https://me24.sequireevents.com/ |
About Kairos Pharma Ltd.
Based in Los Angeles, California, Kairos Pharma Ltd. (NYSE American: KAPA) is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Our lead candidate, ENV105, is an antibody that targets CD105—a protein identified as a key driver of resistance to various cancer treatments. Elevation of CD105 in response to standard therapy results in resistance and disease relapse. ENV105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV105 is in a Phase 2 clinical trial for castrate resistant prostate cancer and a Phase 1 trial for lung cancer, addressing significant unmet medical needs. For more information, visit kairospharma.com.
CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements as those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential” or “hopes” or the negative of these or similar terms. The reader is cautioned not to rely on these forward-looking statements. If underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Kairos Pharma. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance. In evaluating these forward-looking statements, you should consider various factors, including: our expectations regarding the success and/or completion of our Phase 1 and Phase 2 clinical trials; our success in completing newly initiated clinical trials, commence new trials, and obtain regulatory approval following the conclusion of such trials; challenges and uncertainties inherent in product research and development; and the uncertainty regarding future commercial success. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking statements discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us, including those described in Kairos Pharma’s prospectus filed with the SEC. We are not obligated to publicly update or revise any forward-looking statement, and Kairos Pharma is not required to update any forward-looking statement as a result of new information or future events or developments, except as required by U.S. federal securities laws.
Contact:
CORE IR
Louie Toma
investors@kairospharma.com
FAQ
When is Kairos Pharma (KAPA) presenting at the LD Micro Main Event XVII?
Where is the LD Micro Main Event XVII being held?
Who will be presenting for Kairos Pharma (KAPA) at the LD Micro Main Event XVII?
How can I watch Kairos Pharma's (KAPA) presentation at the LD Micro Main Event XVII?
What type of company is Kairos Pharma (KAPA)?
